



John A. Ragan

John A. Ragan was born and raised in Kansas City, Missouri. He received his undergraduate degree in chemistry from MIT in 1985, where he performed undergraduate research under the tutelage of Rick Danheiser. He then joined Stuart Schreiber's group at Yale in 1985, moving to Harvard in 1988, where he completed his Ph.D. in 1990 on the total synthesis of FK506. He was an American Cancer Society postdoctoral fellow with Clayton Heathcock at UC-Berkeley from 1990-92, where he studied the biomimetic synthesis of the daphniphyllum alkaloids.

He joined Pfizer in Groton, Connecticut, working initially in Discovery Chemistry from 1992-96. In 1996, he moved to the Process Research Group, and has been in Chemical R&D at Pfizer to the present date. He has worked in both early and late stage development programs, in therapeutic areas including CNS, obesity, hepatitis C, familial amyloid polyneuropathy, oncology, and diabetes. He recently led the team that developed and filed the commercial synthesis of the SGLT2 inhibitor ertugliflozin.

Ragan is co-author of over 50 publications, 10 patents, and has edited three books, including volume 86 of *Organic Syntheses*. He currently serves on the Editorial Advisory Board of the *Journal of Organic Chemistry*. Outside of chemistry, he is a jazz pianist and trumpeter, and a poker aficionado.